James Sterner, MD
Allergy & Immunology · Overland Park, KSNPI 1336361948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $760 and has fallen 71.6% since, to $216 in 2025. That places this record below the midpoint for allergy & immunology clinicians in KS, where the typical reported total is $2,551.
Across 158 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$535
- AstraZeneca$522
- GSK$220
- Takeda Pharmaceuticals U.S.A., Inc.$174
- Hospira, Inc.$145
- Biocryst US Sales Co., LLC$124
- plus $954 from 20 others
Across 51 payments — averaging $1748.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$48K
- Acrotech Biopharma Inc.$19K
- Currax Pharmaceuticals LLC$14K
- Teva Pharmaceuticals USA, Inc.$9K
What the payments were for
- Consulting fees$371%
- Food & beverage$2,63799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 39 | $535 |
| AstraZeneca | 28 | $522 |
| GSK | 14 | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $174 |
| Hospira, Inc. | 9 | $145 |
| Biocryst US Sales Co., LLC | 7 | $124 |
| CSL Behring | 5 | $96 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| LEO Pharma Inc. | 4 | $84 |
| Amgen | 5 | $81 |
| Grifols USA, LLC | 3 | $75 |
| Genentech USA, Inc. | 4 | $59 |
| Hikma Pharmaceuticals USA | 3 | $50 |
| Pharming Healthcare, Inc. | 3 | $49 |
| Novartis | 3 | $48 |
| AbbVie | 2 | $45 |
| Lilly USA, LLC | 3 | $45 |
| Greer Laboratories, Inc. | 2 | $38 |
| ADMA Biomanufacturing LLC | 2 | $37 |
| Pfizer | 2 | $36 |
| Boehringer Ingelheim | 1 | $24 |
| Kaleo, Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $22 |
| Regeneron | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$121
How this compares
$2,675 in reported general payments places this provider in the 50th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $70,708 |
| XolairOmalizumab | 14 | $38,407 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $24,303 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $13,379 |
| Spiriva RespimatTiotropium Bromide | 15 | $12,760 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $12,686 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,755 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $7,105 |
| Arnuity ElliptaFluticasone Furoate | 23 | $6,477 |
| DuleraMometasone/Formoterol | 14 | $5,257 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $4,774 |
| Azelastine Hcl | 141 | $4,269 |
| Epinephrine | 21 | $4,177 |
| Fluticasone Propionate | 142 | $3,001 |
| Ipratropium Bromide | 77 | $2,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $220 | $106,261153 claims |
| Boehringer IngelheimSpiriva Respimat | $24 | $12,76015 claims |
| AstraZenecaBreztri Aerosphere | $522 | $8,75511 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $50 | $6,74432 claims |
| MerckDulera | $16 | $5,25714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 33 allergy & immunology providers in Kansas.
Other allergy & immunology in Overland Park
- Henry KanarekOverland Park$143K
- Celina BernabeOverland Park$95K
- William LaveryOverland Park$25K
- Sara AzzamOverland Park$19K
- Nguyen TranOverland Park$15K
- Cori PasserOverland Park$14K
- Derrick WardOverland Park$6K
- Mark NeustromOverland Park$3K
- H LevineOverland Park$3K
- Khaled GirgisOverland Park$636
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.